Cell Reports (May 2014)

CTCF Haploinsufficiency Destabilizes DNA Methylation and Predisposes to Cancer

  • Christopher J. Kemp,
  • James M. Moore,
  • Russell Moser,
  • Brady Bernard,
  • Matt Teater,
  • Leslie E. Smith,
  • Natalia A. Rabaia,
  • Kay E. Gurley,
  • Justin Guinney,
  • Stephanie E. Busch,
  • Rita Shaknovich,
  • Victor V. Lobanenkov,
  • Denny Liggitt,
  • Ilya Shmulevich,
  • Ari Melnick,
  • Galina N. Filippova

DOI
https://doi.org/10.1016/j.celrep.2014.04.004
Journal volume & issue
Vol. 7, no. 4
pp. 1020 – 1029

Abstract

Read online

Epigenetic alterations, particularly in DNA methylation, are ubiquitous in cancer, yet the molecular origins and the consequences of these alterations are poorly understood. CTCF, a DNA-binding protein that regulates higher-order chromatin organization, is frequently altered by hemizygous deletion or mutation in human cancer. To date, a causal role for CTCF in cancer has not been established. Here, we show that Ctcf hemizygous knockout mice are markedly susceptible to spontaneous, radiation-, and chemically induced cancer in a broad range of tissues. Ctcf+/− tumors are characterized by increased aggressiveness, including invasion, metastatic dissemination, and mixed epithelial/mesenchymal differentiation. Molecular analysis of Ctcf+/− tumors indicates that Ctcf is haploinsufficient for tumor suppression. Tissues with hemizygous loss of CTCF exhibit increased variability in CpG methylation genome wide. These findings establish CTCF as a prominent tumor-suppressor gene and point to CTCF-mediated epigenetic stability as a major barrier to neoplastic progression.